Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.51 |
| ▸ | TSHR | P16473 | 4/20 | 0.51 |
| ▸ | CRHBP | P24387 | 1/20 | 0.51 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | QPCT | Q16769 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6982586 | 0.81 | TSHR (0.45) | NPSR1TSHRSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL6979322 | 0.81 | TSHR (0.53) | NPSR1TSHRSMN1; SMN2ALDH1A1POLB | |
| SCHEMBL6978069 | 0.80 | TSHR (0.59) | NPSR1TSHRALDH1A1POLBGAA | |
| SCHEMBL6977516 | 0.79 | PGR (0.58) | NPSR1TSHRSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL7655121 | 0.79 | NPSR1 (0.58) | NPSR1TSHRCRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL6979646 | 0.78 | TSHR (0.52) | NPSR1TSHRALDH1A1GAAKMT2A | |
| SCHEMBL6981518 | 0.77 | TSHR (0.50) | NPSR1TSHRKDM4EGAAKMT2A | |
| SCHEMBL6978222 | 0.77 | TSHR (0.50) | NPSR1TSHRALDH1A1GAAKMT2A | |
| SCHEMBL6982149 | 0.76 | TSHR (0.57) | NPSR1TSHRALDH1A1GAAKMT2A | |
| SCHEMBL6969321 | 0.76 | TSHR (0.57) | NPSR1TSHRSMN1; SMN2ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030199530-A1 | New compounds derived from quinazoline | LES LABORATORIES SERVIER (FR) | 2003-10-23 | — | — | US | disclosed |
| EP-1346992-A1 | Quinazoline derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199530-A1 | New compounds derived from quinazoline | NQO2, XDH, DRD1 | NPSR1 1340/4885TSHR 3090/4885CRHBP 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.